ALLMedicine™ Erythroleukemia Center
Research & Reviews 325 results
https://doi.org/10.1182/bloodadvances.2020003521
Blood Advances; Kohrogi K, Hino S et. al.
Apr 30th, 2021 - Acute myeloid leukemia (AML) is a heterogenous malignancy characterized by distinct lineage subtypes and various genetic/epigenetic alterations. As with other neoplasms, AML cells have well-known aerobic glycolysis, but metabolic variations depend...
https://doi.org/10.1007/s11912-021-01060-8 10.1182/blood.V7.8.765.765 10.1182/blood.V6.4.372.372 10.1111/j.1365-2141.1976.tb03563.x 10.1182/blood.V68.5.1167.1167 10.1093/ajcp/98.1.34 10.1093/ajcp/110.5.590 10.7326/0003-4819-103-4-626 10.1182/blood-2016-03-643544 10.1586/ehm.10.62 10.1002/pbc.20951 10.1182/blood-2009-09-243964 10.1182/blood.V80.11.2873.2873 10.1093/ajcp/aqw033 10.1038/modpathol.2017.175 10.1016/j.path.2013.08.006 10.1182/blood.V61.4.645.645 10.1002/ajh.2830290104 10.1111/j.1365-2141.1995.tb05208.x 10.1093/ajcp/aqx018 10.1038/modpathol.2016.118 10.1016/j.cancergencyto.2005.05.006 10.1038/leu.2013.144 10.1038/leu.2015.198 10.1371/journal.pone.0172029 10.1038/leu.2016.163 10.1182/blood-2016-11-749903 10.1038/s41588-019-0375-1 10.1371/journal.pone.0063663 10.1023/A:1011133115435 10.1038/leu.2009.181 10.1182/blood.V128.22.5204.5204 10.1056/NEJMoa1605949 10.3390/ijms18040837 10.3109/10428194.2015.1079318
Current Oncology Reports; Weinberg OK, Arber DA
Apr 20th, 2021 - Acute erythroleukemia (AEL) is a rare form of acute myeloid leukemia recognized by erythroblastic proliferation. Many controversies remain around diagnosis influencing prognostic and therapeutic implications relating to this unique leukemia subset...
https://doi.org/10.3892/or.2021.8048
Oncology Reports; Geng Y, Wu W et. al.
Apr 13th, 2021 - The aim of the present study was to investigate the synergistic effect of LY294002 (a PI3K inhibitor) and ABT199 (a BCL2 inhibitor) on the cell cycle in acute myeloid leukemia (AML). The optimal concentration and duration of combined LY294002 and ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995291
Blood Iacobucci I, Qu C et. al.
Jan 29th, 2021 - Acute erythroid leukemia (AEL) is characterized by a distinct morphology, mutational spectrum, lack of preclinical models, and poor prognosis. Here, using multiplexed genome editing of mouse hematopoietic stem and progenitor cells and transplant a...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925369
Molecular Cancer Research : MCR; Reilly BM, Luger T et. al.
Nov 11th, 2020 - DNA methyltransferase inhibitors (DNMTI) like 5-Azacytidine (5-Aza) are the only disease-modifying drugs approved for the treatment of higher-risk myelodysplastic syndromes (MDS), however less than 50% of patients respond, and there are no predict...
Clinicaltrials.gov 325 results
https://doi.org/10.1182/bloodadvances.2020003521
Blood Advances; Kohrogi K, Hino S et. al.
Apr 30th, 2021 - Acute myeloid leukemia (AML) is a heterogenous malignancy characterized by distinct lineage subtypes and various genetic/epigenetic alterations. As with other neoplasms, AML cells have well-known aerobic glycolysis, but metabolic variations depend...
https://doi.org/10.1007/s11912-021-01060-8 10.1182/blood.V7.8.765.765 10.1182/blood.V6.4.372.372 10.1111/j.1365-2141.1976.tb03563.x 10.1182/blood.V68.5.1167.1167 10.1093/ajcp/98.1.34 10.1093/ajcp/110.5.590 10.7326/0003-4819-103-4-626 10.1182/blood-2016-03-643544 10.1586/ehm.10.62 10.1002/pbc.20951 10.1182/blood-2009-09-243964 10.1182/blood.V80.11.2873.2873 10.1093/ajcp/aqw033 10.1038/modpathol.2017.175 10.1016/j.path.2013.08.006 10.1182/blood.V61.4.645.645 10.1002/ajh.2830290104 10.1111/j.1365-2141.1995.tb05208.x 10.1093/ajcp/aqx018 10.1038/modpathol.2016.118 10.1016/j.cancergencyto.2005.05.006 10.1038/leu.2013.144 10.1038/leu.2015.198 10.1371/journal.pone.0172029 10.1038/leu.2016.163 10.1182/blood-2016-11-749903 10.1038/s41588-019-0375-1 10.1371/journal.pone.0063663 10.1023/A:1011133115435 10.1038/leu.2009.181 10.1182/blood.V128.22.5204.5204 10.1056/NEJMoa1605949 10.3390/ijms18040837 10.3109/10428194.2015.1079318
Current Oncology Reports; Weinberg OK, Arber DA
Apr 20th, 2021 - Acute erythroleukemia (AEL) is a rare form of acute myeloid leukemia recognized by erythroblastic proliferation. Many controversies remain around diagnosis influencing prognostic and therapeutic implications relating to this unique leukemia subset...
https://doi.org/10.3892/or.2021.8048
Oncology Reports; Geng Y, Wu W et. al.
Apr 13th, 2021 - The aim of the present study was to investigate the synergistic effect of LY294002 (a PI3K inhibitor) and ABT199 (a BCL2 inhibitor) on the cell cycle in acute myeloid leukemia (AML). The optimal concentration and duration of combined LY294002 and ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995291
Blood Iacobucci I, Qu C et. al.
Jan 29th, 2021 - Acute erythroid leukemia (AEL) is characterized by a distinct morphology, mutational spectrum, lack of preclinical models, and poor prognosis. Here, using multiplexed genome editing of mouse hematopoietic stem and progenitor cells and transplant a...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925369
Molecular Cancer Research : MCR; Reilly BM, Luger T et. al.
Nov 11th, 2020 - DNA methyltransferase inhibitors (DNMTI) like 5-Azacytidine (5-Aza) are the only disease-modifying drugs approved for the treatment of higher-risk myelodysplastic syndromes (MDS), however less than 50% of patients respond, and there are no predict...
